The core value of FDA warning letters is that they clearly show “which practices do not comply with regulations”. The violations they list (such as quality system deficiencies, failed design controls and labelling errors) are effectively “cautionary examples” for companies’ self-inspection and correction. Specifically, they help in the following ways:
(1) Companies can use real cases to understand how abstract provisions apply in practice
For example, if a warning letter mentions “failure to perform design validation of software updates (820.30(g))”, other companies can check whether their own software iteration process meets this requirement.
(2) Analysing warning letters in bulk reveals the risk areas the FDA is currently focusing on
For example, “cybersecurity vulnerabilities”, “insufficient AI algorithm validation” and “clinical data integrity issues” appeared frequently in 2023–2025. Companies can strengthen these areas accordingly to avoid becoming the next target of enforcement.
(3) Issues mentioned in warning letters, such as “sterile barrier failure” and “electrical safety defects”, may lead to product recalls or patient harm
Companies can check their own production processes (such as sterilisation processes and equipment calibration) against them to avoid recalls caused by similar issues (FDA data show that about 30% of medical device recalls stem from quality system deficiencies commonly cited in warning letters).
(4) By analysing warning letters for similar products
(for example, a type of IVD reagent warned for “insufficient performance validation”), companies can improve their validation data in advance and avoid suspension of sales after launch due to compliance problems.
1. Searching FDA warning letters to medical device companies: go directly to the FDA’s official warning letters page via the following link
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters.
The page looks like this:
How to use the “Search” and “Filter by” options shown above, in one chart:
2. Understanding the logic behind warning letters
-
Link with FDA Form 483: a warning letter is usually the FDA’s follow-up when a company fails to effectively correct Form 483 observations. For example, a pharmaceutical company received a warning letter in July 2024 for failing to fully address deficiencies in a 2024 FDA Form 483. You can therefore also check the FDA Form 483 page (e.g. https://www.fda.gov/drugs/cder-foia-electronic-reading-room/frequently-requested-or-proactively-posted-compliance-records) to track corrective actions.
-
Interpreting category labels: warning letters indicate the type of violation – for example, that a company’s production process does not comply with the Quality System Regulation (21 CFR 820), or that a company has labelling or IFU issues.
-
Searching historical archives
Warning letters older than 3 years are archived.
Go to https://www.fda.gov/archives and enter the company name or year to search historical records.
More articles:
Clinical Evaluation Routes and Methods in MDR Certification
Guide to Writing MDR Technical Documentation
EU Safety Rules for Medical Device Apps on Online Platforms
Introduction to EU MDR Class IIa Products
Introduction to EU MDR Class IIb Products
How to Look Up US 21 CFR Regulations
FDA Medical Device Product Codes
Finding Core Information on Predicate Devices on the FDA Website